Survey finds 1 in 10 new cases of TB in China are drug-resistant

NewsGuard 100/100 Score

"One in 10 cases of tuberculosis in China cannot be treated by the most commonly-used drugs, driven by a lack of testing and misuse of medicine, according to a national survey that showed for the first time the size of the drug-resistant epidemic," the Associated Press reports (Wong, 6/7). "'In 2007, one third of the patients with new cases of tuberculosis and one half of the patients with previously treated tuberculosis had drug-resistant disease,' said the study in the New England Journal of Medicine," Agence France-Presse reports, adding, "Even more, the prevalence of multi-drug resistant [tuberculosis (MDR-TB)] in new cases (5.7 percent) was nearly twice the global average, said the study" (6/6).

"The survey of more than 4,000 Chinese patients, conducted in 2007, follows a warning from the [WHO] last year that multi drug-resistant and extensively drug-resistant forms of TB are also spreading at an alarming rate in Europe," Reuters writes. "Health experts are calling for faster testing of the nine million people worldwide estimated to be infected with tuberculosis each year," the news service adds (Kelland, 6/6). In an editorial accompanying the study, Richard Chaisson and Eric Nuermberger of the Center for Tuberculosis Research at the Johns Hopkins University School of Medicine examine how "resistance became so prevalent in China" and discuss the "unmet need" for treatment (6/7).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer